Short Interest in Nykode Therapeutics AS (OTCMKTS:VACBF) Rises By 83.1%

Nykode Therapeutics AS (OTCMKTS:VACBF) saw a significant growth in short interest in February. As of February 15th, there was short interest totalling 2,193,400 shares, a growth of 83.1% from the January 31st total of 1,197,800 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is currently ∞ days.

Nykode Therapeutics AS Stock Performance

Shares of Nykode Therapeutics AS stock opened at $0.22 on Monday. Nykode Therapeutics AS has a fifty-two week low of $0.22 and a fifty-two week high of $0.95. The firm has a 50-day simple moving average of $0.24 and a two-hundred day simple moving average of $0.41.

About Nykode Therapeutics AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10.